久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Keytruda combo wins FDA approval for RCC pharmatimes
    April 25, 2019
    The US Food and Drug Administration (FDA) has approved MSD’s Keytruda?(pembrolizumab), in combination with Inlyta(axitinib), as first-line treatment for patients with advanced renal cell carcinoma (RCC).
  • Keytruda combo set to become “standard of care” in kidney cancer pharmaphorum
    February 19, 2019
    Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care in renal cell carcinoma (RCC) thanks to impressive trial results and a price advantage over BMS’ rival drug.....
PharmaSources Customer Service